Patent ID: 11912784
Assignee: KODIAK SCIENCES INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 42:
43. A method of disease modification of an eye disorder, wherein the method comprises:
administering an anti-VEGF antibody conjugate to a subject having an eye disorder at a first loading dose, wherein the eye disorder is wet age-related macular degeneration (wAMD),
wherein the anti-VEGF antibody conjugate comprises:
an antibody conjugate comprising a light chain and a heavy chain, wherein the heavy chain comprises CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and the light chain comprises CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13), and CDRL3: QQYSTVPWT (SEQ ID NO: 14), and wherein the heavy chain comprises an amino acid sequence at least 90% identical to SEQ ID NO: 1 and the light chain comprises an amino acid sequence at least 90% identical to SEQ ID NO: 2; and
a phosphorylcholine containing polymer covalently bonded to the heavy chain, wherein the polymer comprises 2-(methacryloyloxyethyl)-2′-(trimethylammonium)ethyl phosphate (MPC) monomers, and wherein the polymer has a molecular weight of between about 600,000 and about 1,000,000 Da,

whereby the eye disorder is modified in a beneficial manner to the subject.